Table 7 Sensitivity analysis results for ranibizumab for the treatment of subfoveal neovascular AMD utilizing a societal cost perspective, average cost-utility analysis (bilateral treatment model unless otherwise specified)

Eye model

 2nd eye model, societal costs

1.372/22.8%

(−$282,517)

(−$205,971)

 2nd eye model, 3rd party insurer costs

1.372/22.8%

$24,082

$17,557

 1st eye model, societal costs

0.680/9.8%

(−$282,517)

(−$415,367)

 1st eye model, 3rd party insurer costs

0.680/9.8%

$24,082

$35,406

 Combined-eye model, societal costs—BASE CASE

1.136/16.3%

(−$282,517)

(−$248,639)

 Combined-eye model, all 3rd party insurer costs

1.136/16.3%

$24,082

$21,194

 Combined-eye model, direct ophthalmic medical costs only

1.136/16.3%

$79,056

$69,592

Costs

 Ranibizumab cost increased 100%

1.136/16.3%

(−$233,271)

(−$205,344)

 Four additional ranibizumab annually, years 3–13

1.136/16.3%

(−$213,910)

(−$188,301)

 Caregiver costs excluded

1.136/16.3%

$15,025

$13,226

 Cost of therapy decreased by 50%

1.136/16.3%

(−$322,045)

(−$283,490)

Treat-and-extend regimen costs (assuming same value gain) [38]^a

 Direct ophthalmic medical costs only, treat-and- extend, no fellow eye treatment costs

1.136/16.3%

$52,250

$45,995

 Current study, direct ophthalmic medical costs, no fellow eye treatment costs

1.136/16.3%

$54,569

$48,036

Value gain

 Patient value gain (QALY gain) drops by 50% for years 5–12, societal costs

0.688/9.9%

(−$282,517)

(−$410,757)

 Patient value gain (QALY gain) drops by 50% years 5–12, 3rd party insurer costs

0.688/9.9%

$24,082

$35,013

Cost-utility

 For cost-utility of $50,000/QALY

1.136/16.3%

$56,800

$50,000

 For cost-utility of $100,000/QALY

1.136/16.3%

$113,600

$100,000